Related Experiment Video
Updated: Aug 10, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
Sickle cell disease: primary stroke prevention
Mehari Gebreyohanns1, Robert J Adams
1Department of Neurology, Medical College of Georgia, Augusta, 30912, USA.
Insights
Stroke is a common complication of sickle cell disease (SCD). Transcranial Doppler ultrasound (TCD) screening and chronic transfusions significantly reduce stroke risk in children with SCD.
Area of Science:
- Neurology
- Hematology
- Pediatrics
Background:
- Stroke is a frequent and serious complication of sickle cell disease (SCD), impacting both children and adults.
- Intracranial artery stenosis or occlusion, leading to moyamoya or infarction, is a common cause of clinically evident stroke in SCD.
- Silent cerebrovascular disease, though often unrecognized, is linked to cognitive and learning impairments.
Purpose of the Study:
- To evaluate the effectiveness of transcranial Doppler ultrasound (TCD) screening and chronic blood transfusions for primary stroke prevention in children with SCD.
- To assess the risk of clinical stroke associated with silent brain lesions detected by magnetic resonance imaging (MRI) in children with SCD.
Main Methods:
- A randomized clinical trial screened over 2,000 young children with SCD using TCD ultrasound to identify elevated blood flow velocities indicating high stroke risk.
- Children identified as high-risk were randomized to either standard care or chronic transfusion therapy.
- Silent brain lesions on MRI were assessed for their association with future clinical stroke risk.
Main Results:
- Children receiving standard care had a 10% annual stroke risk, which was reduced by over 90% with chronic transfusions.
- Silent brain lesions on MRI are associated with an approximate 1.5% annual risk of clinical stroke.
- TCD screening and transfusion represent the only proven primary stroke prevention strategy in SCD tested in a randomized controlled trial.
Conclusions:
- Chronic blood transfusion therapy, guided by TCD screening, is highly effective in preventing clinical stroke in children with SCD.
- Further research and broader implementation of TCD screening are crucial for reducing stroke incidence in children with SCD.
- Ongoing trials are investigating interventions for nocturnal hypoxemia and exploring other potential preventive agents like hydroxyurea.
Abstract:
Stroke is an important and common complication of sickle cell disease (SCD), affecting children as well as adults. Clinically evident stroke, usually brain infarction, is usually associated with stenosis or occlusion of the intracranial arteries of the Circle of Willis, sometimes with formation of moyamoya (a Japanese word for "hazy" or "like a puff of smoke" that describes the appearance of a abnormal microvasculature on angiography believed secondary to internal carotid artery stenosis or occlusion and the resultant extensive collateralization). Several types of intracranial hemorrhage are observed but usually in older children and adults. Cerebrovascular diseases restricted to small vessels may go unrecognized but is associated with cognitive and learning problems. Prevention of recurrent stroke has been accomplished with chronic blood transfusion. A primary prevention strategy for clinical stroke, based on the Stroke Prevention in Sickle Cell Anemia Trial, has been tested in a randomized clinical trial. Over 2,000 young children with SCD were screened with transcranial Doppler ultrasound (TCD) to detect elevated blood flow velocity indicative of vessel disease and high risk of future stroke. Those randomized to standard care (no transfusion) had a 10%/year risk of stroke, which was reduced >90% with chronic transfusion. This approach is the only primary stroke prevention strategy so far tested in SCD in a randomized controlled trial. Silent lesions on magnetic resonance imaging are associated with an approximately 1.5%/year risk of clinical stroke and a trial is now starting in children with these lesions who do not meet Stroke Prevention in Sickle Cell Anemia Trial criteria for transfusion based on TCD. A controlled trial, based on intervention for nocturnal hypoxemia, is also underway. Hydroxyurea, bone marrow transplantation, antiplatelet, and antithrombotic agents may work but have not been tested in primary prevention in a systematic way. If early and repeated, TCD screening of children, as recommended by National Heart Lung and Blood Institute and the American Stroke Association, were implemented broadly the incidence of new strokes could be greatly reduced in these children.
More Related Videos
Related Concept Videos
Atherosclerosis IV: Nursing Management
Venous Thrombosis III: Interprofessional Care
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology

